The Muscular Dystrophy Association (MDA) and Target ALS Foundation announce a partnership, with its goal being to help advance ALS research and therapy development.
Via the partnership, the organizations will work together to support young scientists who are seeking a career devoted to ALS research, according to a media release from MDA.
MDA awards Development Grants to these scientists, funded at $60,000 per year for three years, to provide support for the development of an independent research project.
Core facilities launched by Target ALS Foundation give ALS researchers access to human postmortem tissue, human stem cells, and viral vectors.
As part of the partnership, Target ALS will extend access to its core facilities to the recipients of MDA’s Development Grants to help the researchers advance their research projects and encourage them to continue pursuing careers within the ALS research field.
“MDA is strategic in our efforts to pursue collaborative partnerships, and we’re excited to align with Target ALS Foundation to advance our common goal of supporting the young ALS researchers today who will make the breakthroughs of tomorrow,” says MDA President and CEO Steven M. Derks, in the release.
“By uniting and working together, we can make certain young scientists at this pivotal stage in their careers have all the resources necessary to advance their research, facilitate discovery, and make the greatest impact in the lives of individuals and families with ALS,” he adds.
“Target ALS is pleased to partner with MDA to expand access of its core facilities to talented young ALS investigators. This partnership is an extension of our core mission to lower barriers for ALS research and ensure that critical tools are available to fast track the best ideas for development of ALS therapeutics,” states Manish Raisinghani, MBBS, PhD, president of Target ALS Foundation Inc, per the release.
[Source(s): Muscular Dystrophy Association, PRWeb]
